TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis
Brief Summary: This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study. Pharmacokinetics of KHK4827 will also be assessed.


Options:
A: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC
B: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control
D: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis
Brief Summary: This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study. Pharmacokinetics of KHK4827 will also be assessed.


Options:
A: Arm Label: 10 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 25 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 75 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 150 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Ixekizumab, Drug: Placebo | Arm Label: 120 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 80 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Intervention Type: BIOLOGICAL; Name: Ixekizumab; Assigned to Arm(s): 10 mg Ixekizumab, 120 mg Ixekizumab, 150 mg Ixekizumab, 25 mg Ixekizumab, 75 mg Ixekizumab, 80 mg Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
C: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth
Brief Summary: Women of reproductive age are considered a high-risk group for worm infections by the World Health Organization. Maternal infection and anemia contribute to infant malnutrition by affecting milk quality and quantity, and duration of exclusive breastfeeding. To date, no study has investigated the health benefits of postpartum deworming to infants or mothers. A randomized controlled trial will be conducted in Peru to investigate the effectiveness of integrating deworming into routine postpartum care. The primary measure of effect will be infant weight gain between birth and six months of age. Other infant and maternal health indicators will also be ascertained.


Options:
A: Arm Label: Alternative SoF; Type: EXPERIMENTAL; Interventions: Other: Alternative summary of findings table format | Arm Label: Current SoF; Type: ACTIVE_COMPARATOR; Interventions: Other: Current summary of findings table format | Intervention Type: OTHER; Name: Alternative summary of findings table format; Assigned to Arm(s): Alternative SoF | Intervention Type: OTHER; Name: Current summary of findings table format; Assigned to Arm(s): Current SoF
B: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: Iron-folic acid and mebendazole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole + Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron-folic acid and mebendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Mebendazole; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Mebendazole + Multivitamin; Assigned to Arm(s): 4
C: Arm Label: Multiple Intervention Arm; Type: EXPERIMENTAL; Interventions: Drug: Albendazole, Dietary Supplement: Zinc, Dietary Supplement: Multiple Micronutrient Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient Supplement; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth
Brief Summary: Women of reproductive age are considered a high-risk group for worm infections by the World Health Organization. Maternal infection and anemia contribute to infant malnutrition by affecting milk quality and quantity, and duration of exclusive breastfeeding. To date, no study has investigated the health benefits of postpartum deworming to infants or mothers. A randomized controlled trial will be conducted in Peru to investigate the effectiveness of integrating deworming into routine postpartum care. The primary measure of effect will be infant weight gain between birth and six months of age. Other infant and maternal health indicators will also be ascertained.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Dietary Supplement: Iron-folic acid and mebendazole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Mebendazole + Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Iron-folic acid and mebendazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Mebendazole; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Mebendazole + Multivitamin; Assigned to Arm(s): 4
B: Arm Label: Community-wide deworming; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Targeted deworming; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albendazole | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Community-wide deworming, Targeted deworming
C: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Praziquantel; Type: EXPERIMENTAL; Interventions: Drug: Praziquantel | Intervention Type: DRUG; Name: Praziquantel; Assigned to Arm(s): Praziquantel | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiorespiratory Fitness and Effect of Training After Lung Cancer Surgery. A Randomized Controlled Trial
Brief Summary: The purpose of the study is to investigate the change in pulmonary function and exercise capacity in lung cancer patients after pulmonary resection. Furthermore, to study the effect of training on aerobic capacity, muscular strength, morbidity and survival. Physical activity level by accelerometers, body composition by DXA and quality of life will also be reported.


Options:
A: Arm Label: 1: exercise with 2 counseling types; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental 1: exercise with 2 counseling types | Arm Label: 2. Usual Care - written materials; Type: OTHER; Interventions: Other: Usual Care - written materials | Intervention Type: BEHAVIORAL; Name: Experimental 1: exercise with 2 counseling types; Assigned to Arm(s): 1: exercise with 2 counseling types | Intervention Type: OTHER; Name: Usual Care - written materials; Assigned to Arm(s): 2. Usual Care - written materials
B: Arm Label: Physical training; Type: OTHER; Interventions: Other: Physical training | Arm Label: As usual; Type: OTHER; Interventions: Other: As usual | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training | Intervention Type: OTHER; Name: As usual; Assigned to Arm(s): As usual
C: Arm Label: Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Rehabilitation Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation Program; Assigned to Arm(s): Rehabilitation Group
D: Arm Label: Delayed exercise control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiorespiratory Fitness and Effect of Training After Lung Cancer Surgery. A Randomized Controlled Trial
Brief Summary: The purpose of the study is to investigate the change in pulmonary function and exercise capacity in lung cancer patients after pulmonary resection. Furthermore, to study the effect of training on aerobic capacity, muscular strength, morbidity and survival. Physical activity level by accelerometers, body composition by DXA and quality of life will also be reported.


Options:
A: Arm Label: PLEACE 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anterolateral thoracotomy, Procedure: Posterolateral thoracotomy | Arm Label: PLEACE 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: VATS, Procedure: Anterolateral Thoracotomy | Intervention Type: PROCEDURE; Name: Anterolateral thoracotomy; Assigned to Arm(s): PLEACE 1 | Intervention Type: PROCEDURE; Name: Posterolateral thoracotomy; Assigned to Arm(s): PLEACE 1 | Intervention Type: PROCEDURE; Name: VATS; Assigned to Arm(s): PLEACE 2 | Intervention Type: PROCEDURE; Name: Anterolateral Thoracotomy; Assigned to Arm(s): PLEACE 2
B: Arm Label: Resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Resistance training
C: Arm Label: Physical training; Type: OTHER; Interventions: Other: Physical training | Arm Label: As usual; Type: OTHER; Interventions: Other: As usual | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training | Intervention Type: OTHER; Name: As usual; Assigned to Arm(s): As usual
D: Arm Label: Inspiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training, Other: Placebo comparator: standard physiotherapy | Arm Label: Standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo comparator: standard physiotherapy | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training | Intervention Type: OTHER; Name: Placebo comparator: standard physiotherapy; Assigned to Arm(s): Inspiratory muscle training, Standard physiotherapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dulce Digital-Project Dulce 2.0 Texting Study in High Risk Latinos With Diabetes
Brief Summary: Randomized controlled trial testing the efficacy of a text messaging intervention in a low income, low health literacy group of Latino patients. Project Dulce 2.0 (PD 2.0) will address barriers to participation in health education classes, increasing adherence to treatment and medications and improving diabetes self management behaviors and skills. Two community clinic organizations that provide services to a large proportion of Latino patients with type 2 diabetes will participate to randomize 200 patients into one of 2 arms: standard diabetes management care (control) only or text messaging and standard care. Comparisons between groups will evaluate clinical, behavioral and psychosocial outcomes.

Intervention: Standard Care and Text Messaging. All participants will receive standard diabetes care provided by primary care providers at the clinic. Of the 100 that are randomized to the intervention arm will be given instructions on how the text messaging component will be addressed throughout the duration of the study.


Options:
A: Arm Label: MEDIC; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral counseling and peer support, Behavioral: Interactive Education, Behavioral: Role modeling, Procedure: Pharmacologic case management | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral counseling and peer support; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Interactive Education; Assigned to Arm(s): MEDIC | Intervention Type: BEHAVIORAL; Name: Role modeling; Assigned to Arm(s): MEDIC | Intervention Type: PROCEDURE; Name: Pharmacologic case management; Assigned to Arm(s): MEDIC
B: Arm Label: SMS texting intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS texting intervention | Arm Label: Control-Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control-Usual Care | Intervention Type: BEHAVIORAL; Name: SMS texting intervention; Assigned to Arm(s): SMS texting intervention | Intervention Type: BEHAVIORAL; Name: Control-Usual Care; Assigned to Arm(s): Control-Usual Care
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group, treatment algorithms; Type: EXPERIMENTAL; Interventions: Other: Treatment Algorithms | Intervention Type: OTHER; Name: Treatment Algorithms; Assigned to Arm(s): Intervention Group, treatment algorithms
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing the Dose of Rehabilitation After Stroke.
Brief Summary: This study is about rehabilitation of arm function after a stroke. The investigators are testing the dosage of therapy that is needed for meaningful recovery of arm and hand function. Dosage of therapy refers to the amount of time (in this case, the total number of hours) that a person participates in treatment. The investigators hope to learn how much therapy time is needed in order for change to occur in arm and hand function after a person has had a stroke. Eligible candidates must have had a stroke affecting the use of an arm or hand at least 6 months ago.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Robot-Assisted Therapy - MIT-MANUS System | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Comparison Therapy | Arm Label: Arm 3; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Robot-Assisted Therapy - MIT-MANUS System; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Intensive Comparison Therapy; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Arm 3
B: Arm Label: High Therapy Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: Moderate Therapy Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: Low Therapy Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: Active Monitoring; Type: OTHER; Interventions: Behavioral: Active Monitoring | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): High Therapy Dose, Low Therapy Dose, Moderate Therapy Dose | Intervention Type: BEHAVIORAL; Name: Active Monitoring; Assigned to Arm(s): Active Monitoring
C: Arm Label: enhanced upper-extremity program, EUEP; Type: EXPERIMENTAL; Interventions: Other: UFT | Arm Label: enhanced lower-extremity program,ELLP); Type: EXPERIMENTAL; Interventions: Other: LFT | Intervention Type: OTHER; Name: UFT; Assigned to Arm(s): enhanced upper-extremity program, EUEP | Intervention Type: OTHER; Name: LFT; Assigned to Arm(s): enhanced lower-extremity program,ELLP)
D: Intervention Type: OTHER; Name: Robot-assisted therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Brief Summary: The purpose of this study is to determine whether roxadustat is safe and effective in the treatment of anemia in participants with chronic kidney disease and not on dialysis.


Options:
A: Arm Label: Roxadustat 0.7 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 0.7 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.0 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.0 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.5 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 1.5 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 2.0 mg/kg BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Roxadustat 2.0 mg/kg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat 0.7 mg/kg BIW, Roxadustat 0.7 mg/kg TIW, Roxadustat 1.0 mg/kg BIW, Roxadustat 1.0 mg/kg TIW, Roxadustat 1.5 mg/kg BIW, Roxadustat 1.5 mg/kg TIW, Roxadustat 2.0 mg/kg BIW, Roxadustat 2.0 mg/kg TIW | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Molidustat group; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo of Darbepoetin alfa | Arm Label: Darbepoetin alfa group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa, Drug: Placebo of Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat group | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa group | Intervention Type: DRUG; Name: Placebo of Molidustat (BAY85-3934); Assigned to Arm(s): Darbepoetin alfa group | Intervention Type: DRUG; Name: Placebo of Darbepoetin alfa; Assigned to Arm(s): Molidustat group
C: Arm Label: Vadadustat; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D